BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34287957)

  • 1. Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells.
    Okamoto K; Saito Y; Ueda H; Narumi K; Furugen A; Kobayashi M
    Biopharm Drug Dispos; 2021 Sep; 42(8):389-392. PubMed ID: 34287957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cystine-glutamate antiporter xCT as a therapeutic target for cancer.
    Liu L; Liu R; Liu Y; Li G; Chen Q; Liu X; Ma S
    Cell Biochem Funct; 2021 Mar; 39(2):174-179. PubMed ID: 32749001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury.
    Meyer AR; Engevik AC; Willet SG; Williams JA; Zou Y; Massion PP; Mills JC; Choi E; Goldenring JR
    Cell Mol Gastroenterol Hepatol; 2019; 8(3):379-405. PubMed ID: 31071489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
    Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
    Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burn injury induces the expression of cystine/glutamate transporter (x(c)(-)) in mouse T cells.
    D'Elia M; Patenaude J; Dupras C; Bernier J
    Immunol Lett; 2009 Aug; 125(2):137-44. PubMed ID: 19576933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transport of cystine across xC
    Ghasemitarei M; Yusupov M; Razzokov J; Shokri B; Bogaerts A
    Arch Biochem Biophys; 2019 Mar; 664():117-126. PubMed ID: 30738038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel analogs of sulfasalazine as system x
    Patel D; Kharkar PS; Gandhi NS; Kaur E; Dutt S; Nandave M
    Drug Dev Res; 2019 Sep; 80(6):758-777. PubMed ID: 31199023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma.
    Nagane M; Kanai E; Shibata Y; Shimizu T; Yoshioka C; Maruo T; Yamashita T
    PLoS One; 2018; 13(4):e0195151. PubMed ID: 29649284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
    Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
    Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The x(c)(-) cystine/glutamate antiporter (xCT) as a potential target for therapy of cancer: yet another cytotoxic anticancer approach?
    Savaskan NE; Hahnen E; Eyüpoglu IY
    J Cell Physiol; 2009 Aug; 220(2):531-2; author reply 533-4. PubMed ID: 19415694
    [No Abstract]   [Full Text] [Related]  

  • 11. A negative correlation between expression profiles of runt-related transcription factor-2 and cystine/glutamate antiporter xCT subunit in ovariectomized mouse bone.
    Uno K; Takarada T; Nakamura Y; Fujita H; Hinoi E; Yoneda Y
    J Pharmacol Sci; 2011; 115(3):309-19. PubMed ID: 21325781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
    Koppula P; Zhuang L; Gan B
    Protein Cell; 2021 Aug; 12(8):599-620. PubMed ID: 33000412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.
    Lien EC; Ghisolfi L; Geck RC; Asara JM; Toker A
    Sci Signal; 2017 Dec; 10(510):. PubMed ID: 29259101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma.
    Dai L; Cao Y; Chen Y; Parsons C; Qin Z
    J Hematol Oncol; 2014 Apr; 7():30. PubMed ID: 24708874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-Activity-Relationship-Aided Design and Synthesis of xCT Antiporter Inhibitors.
    Cirillo D; Sarowar S; Øyvind Enger P; Bjørsvik HR
    ChemMedChem; 2021 Sep; 16(17):2650-2668. PubMed ID: 33847044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling.
    Liu J; Xia X; Huang P
    Mol Ther; 2020 Nov; 28(11):2358-2366. PubMed ID: 32931751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure, function, and regulation of human cystine/glutamate transporter in retinal pigment epithelial cells.
    Bridges CC; Kekuda R; Wang H; Prasad PD; Mehta P; Huang W; Smith SB; Ganapathy V
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):47-54. PubMed ID: 11133847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.
    Ji X; Qian J; Rahman SMJ; Siska PJ; Zou Y; Harris BK; Hoeksema MD; Trenary IA; Heidi C; Eisenberg R; Rathmell JC; Young JD; Massion PP
    Oncogene; 2018 Sep; 37(36):5007-5019. PubMed ID: 29789716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystine/glutamate antiporter blockage induces myelin degeneration.
    Soria FN; Zabala A; Pampliega O; Palomino A; Miguelez C; Ugedo L; Sato H; Matute C; Domercq M
    Glia; 2016 Aug; 64(8):1381-95. PubMed ID: 27247047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.